Clinical impact of direct-acting antiviral treatment on patients with hepatitis C virus–related oral lichen planus

2021 ◽  
Vol 131 (4) ◽  
pp. e113
Author(s):  
Dario Di Stasio ◽  
Marco Di Petrillo ◽  
Antonio Romano ◽  
Fausto Fiori ◽  
Diana Russo ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Antiviral Treatment ◽  
Clinical Impact ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Oral Lichen

Clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus

2020 ◽  
Vol 73 ◽  
pp. S617
Author(s):  
Marco Di Petrillo ◽  
Dario Di Stasio ◽  
Riccardo Nevola ◽  
Luca Rinaldi ◽  
Luigi Elio Adinolfi ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Antiviral Treatment ◽  
Clinical Impact ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Oral Lichen

scholarly journals Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma

2017 ◽  
Vol 11 (3) ◽  
pp. 701-710 ◽  
Author(s):  
Yumiko Nagao ◽  
Kazunori Nakasone ◽  
Tatsuji Maeshiro ◽  
Nao Nishida ◽  
Kanae Kimura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Immunosuppressive Drugs ◽  
Hcv Infection ◽  
Direct Acting ◽  
Oral Lichen

Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP accompanied by HCV-related hepatocellular carcinoma (HCC) that disappeared after liver transplantation and achievement of sustained virological response following interferon (IFN)-free treatment with ledipasvir (LDV) and sofosbuvir (SOF). The 50-year-old patient developed erosive OLP during IFN therapy, with hyperthyroidism at 53 years of age and HCC at 55 years. He received immunosuppressive drugs and IFN-free DAA treatment after liver transplantation at 60 years of age, which led to disappearance of the symptoms of OLP. The patient was treated safely and effectively with LDV/SOF, although it is not known whether the disappearance of OLP resulted from the eradication of HCV or the immunosuppressive therapy.

scholarly journals Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

2018 ◽  
Vol 18 (3) ◽  
pp. 217-223 ◽  
Author(s):  
Alexandru Mester ◽  
Ondine Lucaciu ◽  
Lidia Ciobanu ◽  
Dragos Apostu ◽  
Aranka Ilea ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Clinical Features ◽  
Oral Lichen Planus ◽  
Hcv Infection ◽  
Adequate Treatment ◽  
Pubmed Database ◽  
Direct Acting ◽  
Oral Lichen

Oral lichen planus (OLP) is a chronic inflammatory disease characterized by the occurrence of multiple, symmetrical lesions in the oral cavity. Hepatitis C virus (HCV) infection has been suggested as an etiological factor in OLP. The purpose of this review was to summarize the current literature regarding the treatment of OLP in patients with HCV infection. An electronic search of the PubMed database was conducted until January 2018, using the following keywords: OLP, HCV, corticosteroids, retinoids, immunomodulatory agents, surgical interventions, photochemotherapy, laser therapy, interferon, ribavirin, and direct-acting antivirals. We selected the articles focusing on the clinical features and treatment management of OLP in patients with/without HCV infection. Topical corticosteroids are considered the first-line treatment in OLP. Calcineurin inhibitors or retinoids can be beneficial for recalcitrant OLP lesions. Systemic therapy should be used in the case of extensive and refractory lesions that involve extraoral sites. Surgical intervention is recommended for isolated lesions. In patients with HCV, monotherapy with interferon (IFN)-α may either improve, aggravate or trigger OLP lesions, while combined IFN-α and ribavirin therapy does not significantly influence the progression of lesions. Direct-acting antiviral (DAA) therapy appears to be a promising approach in patients with HCV-related OLP, as it can improve symptoms of both liver disease and OLP, with fewer side effects. Nevertheless, for clinical utility of DAAs in OLP patients, further studies with larger sample sizes, adequate treatment duration, and long term follow-up are required.

scholarly journals Use of Direct-Acting Antivirals for the Treatment of Hepatitis C Virus-Associated Oral Lichen Planus: A Case Report

2016 ◽  
Vol 10 (3) ◽  
pp. 617-622 ◽  
Author(s):  
Kenji Misaka ◽  
Takashi  Kishimoto ◽  
Yuji Kawahigashi ◽  
Michio Sata ◽  
Yumiko Nagao
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Therapeutic Effects ◽  
Direct Acting Antivirals ◽  
Extrahepatic Manifestations ◽  
Long Term Follow Up ◽  
Direct Acting ◽  
Oral Lichen

Hepatitis C virus (HCV) is frequently associated with various extrahepatic manifestations such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one of the representative extrahepatic manifestations of HCV infection. Direct-acting antivirals (DAA) are highly effective and safe for the eradication of HCV. However, there is a lack of information regarding the association between HCV-associated OLP and interferon (IFN)-free DAA therapy. Herein, we present the case of a 60-year-old female who was diagnosed with OLP during routine periodontal treatment by a dentist. The patient was referred for hepatitis C treatment using IFN-free DAA, which resulted in the improvement of the symptoms of OLP. This case represents the safety and efficacy of IFN-free DAAs in patients with HCV-associated OLP. However, long-term follow-up studies are required to elucidate the therapeutic effects of this therapy in these patients.

scholarly journals Hepatitis C virus infections in oral lichen planus: a systematic review and meta-analysis

2016 ◽  
Vol 61 (3) ◽  
pp. 282-287 ◽  
Author(s):  
NA Alaizari ◽  
SA Al-Maweri ◽  
HM Al-Shamiri ◽  
B Tarakji ◽  
B Shugaa-Addin
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Meta Analysis ◽  
Virus Infections ◽  
Oral Lichen

Changes in Serum Level of Autotaxin with Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khaled Mohamed Hussein Abdelwahab ◽  
Shereen Abou Bakr Saleh ◽  
Ghada Abdelrahman Ahmed ◽  
Asmaa Mady Gomaa Mady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Serum Level ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Post Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Background Hepatitis C virus virus is global health burden and major health hazard in Egypt, since the virus is the etiological factor of chronic hepatitis. Hepatitis C virus (HCV) accounts for approximately 15%-20% cases of acute hepatitis. After acute infection, around 50% to 80% of HCV patients will develop chronic infection. Approximately, HCV infects 170 million individuals worldwide). Chronic hepatitis C (CHC) patients are at high risk to develop lifethreatening complications, including cirrhosis in 20% of cases and hepatocellular carcinoma. Objectives The aim of this study was to validate Changes in serum level of autotaxin in patients with chronic hepatitis C before and after antiviral treatment. Patients and methods This study was designed as a prospective observational cohort study to evaluate Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C before (baseline) and after (sustained virologic response week 12) treatment. This prospective study was conducted on 48 chronic HCV infected patients eligible for antiviral treatment with direct acting antivirals, agreeable to regular follow up, recruited from Hepatology and virology outpatient clinic at DMNI (Damanhour Medical National Institute) during the period from September 2018 till Mars 2019. Results This study showed that Autotaxin level significantly decreased from baseline to 12 weeks post-treatment. ATX therefore represents a novel non-invasive biomarker for liver fibrosis and a prognostic indicator of disease activity. Conclusion Serum Autotaxin was found to be higher in chronic hepatitis c and ATX levels became significantly decreased from baseline to 12 weeks post-treatment with direct acting antiviral drugs in patients achieving a SVR.

Hepatitis C virus-associated oral lichen planus: is the geographical heterogeneity related to HLA-DR6?

2005 ◽  
Vol 34 (4) ◽  
pp. 204-208 ◽  
Author(s):  
M. Carrozzo ◽  
F. Brancatello ◽  
E. Dametto ◽  
P. Arduino ◽  
M. Pentenero ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Geographical Heterogeneity ◽  
Oral Lichen
Sign in / Sign up

Export Citation Format

Share Document